CGT has made a great breakthrough in the recent years, however the industry is facing challenges in developing stable and scalable manufacturing process for viral vectors. ProBio is dedicated in developing platforms to produce viral vectors, and currently it has robust viral vector manufacturing processes using both adherent culture and suspension culture. ProBio has vast experience in assisting several customers to submit IND to FDA and NMPA, and supporting manufacturing for clinical phase use.